Isolated right adrenal metastasis from an invasive ductal breast carcinoma.

2019 ◽  
pp. 10-12

Invasive ductal carcinoma (IDC) is the most common histopathological type of breast cancer, accounting for up to 85% of all invasive breast carcinomas [1]. It spreads usually to the bone first. Solitary metastasis is commonly located in the lung, liver or brain [2]. Adrenal glands locations are extremely rare [3]. We report a case of isolated metachronous right adrenal metastasis, diagnosed four years after breast IDC management. The aim is to highlight clinical, diagnostic and therapeutic characteristics of this entity.

2019 ◽  
pp. 10-13

Invasive ductal carcinoma (IDC) is the most common histopathological type of breast cancer, accounting for up to 85% of all invasive breast carcinomas [1]. It spreads usually to the bone first. Solitary metastasis is commonly located in the lung, liver or brain [2]. Adrenal glands locations are extremely rare [3]. We report a case of isolated metachronous right adrenal metastasis, diagnosed four years after breast IDC management. The aim is to highlight clinical, diagnostic and therapeutic characteristics of this entity.


2019 ◽  
pp. 10-12

Invasive ductal carcinoma (IDC) is the most common histopathological type of breast cancer, accounting for up to 85% of all invasive breast carcinomas [1]. It spreads usually to the bone first. Solitary metastasis is commonly located in the lung, liver or brain [2]. Adrenal glands locations are extremely rare [3]. We report a case of isolated metachronous right adrenal metastasis, diagnosed four years after breast IDC management. The aim is to highlight clinical, diagnostic and therapeutic characteristics of this entity.


2019 ◽  
pp. 10-13

Invasive ductal carcinoma (IDC) is the most common histopathological type of breast cancer, accounting for up to 85% of all invasive breast carcinomas [1]. It spreads usually to the bone first. Solitary metastasis is commonly located in the lung, liver or brain [2]. Adrenal glands locations are extremely rare [3]. We report a case of isolated metachronous right adrenal metastasis, diagnosed four years after breast IDC management. The aim is to highlight clinical, diagnostic and therapeutic characteristics of this entity.


Author(s):  
Musa Azhar ◽  
Syed Abdul Mannan Hamdani ◽  
Jhanzeb Iftikhar ◽  
Waqas Ahmad ◽  
Sajid Mushtaq ◽  
...  

Breast cancer is the commonest cancer among females and has a high propensity to metastasize, but gynaecological organs are rarely affected. We report a case where invasive ductal carcinoma of the breast metastasized to the uterus after initial management with curative intent. Our patient was on tamoxifen, which can cause endometrial hyperplasia and lead to a challenge in eventual diagnosis.


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12557-e12557
Author(s):  
Emily Clarke ◽  
James George ◽  
Andrew Peter Dean

e12557 Background: With the exception of malignant melanoma, metastases to the GI tract are rare, especially as a first presentation of malignancy. We report a series of patients with GI metastases from lobular breast carcinoma as an unusual source of symptomatic GI bleeding. Methods: We conducted an electronic database search to identify solid tumour patients (excluding melanoma) with metastases to the GI tract. We then analysed the database by tumour type. Results: 3 cases of proven metastasis to the GI tract were identified. All had lobular breast cancer metastases. The database contained 240 patients with breast cancer, identifying 63 with infiltrating lobular carcinoma, 2 with micropapillary and 175 with invasive ductal carcinoma The 1st case had had invasive ductal breast carcinoma 6 years previously and presented with fatigue and shortness of breath from anaemia. Colonoscopy revealed a polyp which was removed. Histopathology showed metastatic lobular breast carcinoma. Further investigation then confirmed an occult breast mass with identical pathology. The 2nd case presented with 18 months of abdominal pain, previous colonoscopy was normal. After onset of anaemia and 25kg weight loss, upper GI endoscopy showed a markedly thickened stomach with evidence of recent bleeding and biopsies confirmed metastatic lobular breast carcinoma. The 3rd case presented with abdominal pain, subsequent blood tests showing a raised CA125 with omental and ovarian masses. Surgical debulking showed metastatic lobular breast carcinoma, though no primary breast lesion was detectable with mammography, ultrasound and MRI. 3 years later, investigation of anaemia with colonoscopy showed a caecal polyp with histology confirming lobular breast carcinoma. Conclusions: Despite all common tumour types being represented in the database it is notable that all 3 cases with mucosal GI metastases had lobular breast cancer. Previous evidence suggests a long latent period from initial diagnosis of breast cancer to development of GI metastases however our report suggests it can occur earlier in the illness. Clinicians should consider this as a rare cause of GI bleeding and further research to understand the mechanism of mucosal metastasis in lobular breast cancer is needed.


2014 ◽  
Vol 142 (9-10) ◽  
pp. 597-601 ◽  
Author(s):  
Natasa Andjelic-Dekic ◽  
Ivana Bozovic-Spasojevic ◽  
Snezana Milosevic ◽  
Miodrag Matijasevic ◽  
Katarina Karadzic

Introduction. Isolated adrenal metastases of invasive ductal breast carcinoma are extremely rare. We report a case with isolated left adrenal metastases, verified three years after diagnosed breast carcinoma. Case Outline. A 58-year-old female patient with a right breast tumor, clinically staged as IIIA (T2N2M0) started neoadjuvant anthracycline chemotherapy after biopsy which revealed invasive ductal breast carcinoma. Immunohistochemical findings of tumor biopsy showed hormonal steroid receptors for estrogen and progesterone negative, and human epidermal growth factor receptor 2 (HER2) positive. After 4 cycles of chemotherapy and partial tumor regression the patient underwent radical mastectomy. Definite histopathological analysis confirmed the diagnosis of invasive ductal carcinoma. The patient continued treatment with adjuvant chemotherapy to cumulative dose of anthracyclines, postoperative radiotherapy and adjuvant trastuzumab for one year. Three years later abdominal computerized tomography showed tumor in the left adrenal gland as the only metastatic site. Left adrenalectomy was performed and histopathological finding confirmed breast cancer metastases. Postoperatively, the patient received 6 cycles of docetaxel with trastuzumab and continued trastuzumab until disease progression. One year after left adrenalectomy control abdominal computerized tomography showed a right adrenal tumor with retroperitoneal lymphadenopathy. Treatment with capecitabine was continued for one year, but eventually she developed brain metastasis causing lethal outcome. Conclusion. In order to better understand metastatic pathways of invasive ductal breast carcinoma, publications of individual patient cases diagnosed with rare metastatic sites should be encouraged. This might improve our understanding of metastatic behavior of breast cancer and stimulate further clinical research.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
San-Gang Wu ◽  
Shi-Ping Yang ◽  
Wen-Wen Zhang ◽  
Jun Wang ◽  
Chen-Lu Lian ◽  
...  

AbstractThe management of metaplastic breast carcinoma (MBC) has largely paralleled the paradigms used for invasive ductal carcinoma (IDC) in the current National Comprehensive Cancer Network guidelines of breast cancer. However, patients with IDC and MBC have been shown to have a different prognosis, and there are significant differences in risk and failure patterns after treatment. The purpose of this study was to compare breast cancer specific survival (BCSS) and hazard function between IDC and MBC. We included patients from the Surveillance, Epidemiology, and End Results program with stage I-III IDC and MBC between 2000 and 2012. Statistical analyses were including chi-square analysis, life-table methods, multivariate Cox proportional hazards models, and propensity score matching (PSM). We identified 294,719 patients; 293,199 patients with IDC and 1520 patients with MBC. Multivariate analyses showed that the MBC subtype had significantly lower BCSS than the IDC subtype before and after PSM (p < 0.001). There were significant differences in the hazard curve between IDC and MBC. The hazard curve for breast cancer mortality in the IDC cohort peaked at 3 years (2%), and then changed to a slowly decreasing plateau after prolonged follow up. However, the hazard curve for breast cancer mortality in the MBC cohort peaked at 2 years (7%), then declined sharply between 3 and 6 years, and changed to a low death rate after a follow-up time exceeding 6 years. Subgroup analyses revealed that the hazard curves significantly differed between IDC and MBC after stratifying by tumor stage and hormone receptor status. Our study suggests that patients with MBC should receive more effective systemic agents and intensive follow-up because of their significantly augmented risk of death compared to IDC patients.


The aim of this study is to determine the accuracy of the preoperative measurement of tumour size, by imaging modalities and whether they deviate from the postoperative pathological measurement in breast cancer. Material and methods: retrospective study done at King Fahad Hospital of University. For two years 2014-2015 all breast cancer patients included studied by reviewing US which was reported by two radiologists and gross size reports by five pathologists. The correlation of ultrasound, with pathology was studied. Results: 118 cases were collected from January 2014 to December 2015 with diagnosis of breast carcinoma. 36 patients were excluded from the study. Finally, a total of 82 were included in the analysis. Invasive ductal carcinoma (IDC) found in 57 patients (69.5%), 44 patients (53.7%) underwent breast conserving surgeries. 46 patient (56.1%) found to be either over or underestimated by US or Pathology. Conclusion: Despite the importance of accuracy of tumour size in management planning this study reflect marked discrepancy in sizes. More collaboration between radiologist and pathologist will yield accurate measurement, which will impact positively on outcome.


2021 ◽  
Vol 10 (18) ◽  
pp. 1296-1301
Author(s):  
Kashifa Rahamath ◽  
Bhawna Dev ◽  
Venkata Sai P.M

BACKGROUND Lobular breast carcinomas have always been a diagnostic challenge, over the years, to the radiologist. They are one of the most commonly missed lesions on breast cancer screening checks, due to their varied presentation. We wanted to provide a concise and practical approach to characterise their morphology and presentation on mammography and ultrasound. METHODS A retrospective study was done for four years and a total of 699 patients with histopathologically proven breast cancer were chosen. Those patients with invasive lobular carcinoma (N = 56) and invasive ductal carcinoma (N = 538) were segregated and 50 cases from each group were selected randomly. RESULTS On mammography, an irregular, high-density mass was the most common presentation of both lobular (68 %) and ductal (86 %) carcinomas. Presentation as focal asymmetry (28 %) was significantly more prevalent in lobular breast carcinomas. Sonographically, an architectural distortion (30 %) and non-parallel orientation (28 %) was predominantly seen in invasive lobular carcinomas (ILCs). Mass (88 %) with micro lobulated (34 %) or angular (22 %) margins was more in favour of ductal carcinoma. Other general parameters like age at presentation, positive family history, multifocality, bilaterality, tumour size and lymph nodal involvement were not significantly different between both the groups. CONCLUSIONS A careful analysis of digital breast tomosynthesis and ultrasonography, keeping in mind all the clear differentiating features, along with experience in the field, will dramatically increase the early detection of lobular breast cancers. KEY WORDS Invasive Lobular Carcinoma (ILC), Invasive Ductal Carcinoma (IDC), X-Ray Mammography, Sono-Mammography


2020 ◽  
Author(s):  
Lungwani Muungo

Purpose: Estrogen-responsive finger protein (Efp) is amember ofRINGfinger-B box-Coiled Coilfamily and is also a downstream target of estrogen receptor a. Previously, Efp was shown tomediate estrogen-induced cell growth, which suggests possible involvement in the developmentof human breast carcinomas. In this study, we examined expression of Efp in breast carcinomatissues and correlated these findings with various clinicopathologic variables.Experimental Design: Thirty frozen specimens of breast carcinomas were used for immunohistochemistryand laser capture microdissection/real-time PCR of Efp. Immunohistochemistryfor Efp was also done in 151breast carcinoma specimens fixed with formalin and embedded inparaffinwax.Results: Efp immunoreactivity was detected in breast carcinoma cells and was significantlyassociated with the mRNA level (n = 30). Efp immunoreactivity was positively associated withlymph node status or estrogen receptor a status and negatively correlated with histologic gradeor 14-3-3j immunoreactivity (n = 151). Moreover, Efp immunoreactivity was significantly correlatedwith poor prognosis of breast cancer patients, and multivariate analyses of disease-freesurvival and overall survival for151breast cancer patients showed that Efp immunoreactivity wasthe independentmarker.Conclusions: Our data suggest that Efp immunoreactivity is a significant prognostic factor inbreast cancer patients. These findings may account for an oncogenic role of Efp in the tumorprogression of breast carcinoma.


Sign in / Sign up

Export Citation Format

Share Document